使用 CD19 靶向 CAR T 细胞治疗两名难治性系统性红斑狼疮儿科患者。

IF 9.2 1区医学 Q1 IMMUNOLOGY

Autoimmunity reviews Pub Date : 2024-11-17 DOI:10.1016/j.autrev.2024.103692

Xue He, Bin Hu, Yingzi Zhang, Fei Liu, Qiuyu Li, Chen Zheng, Junjie Shen, Zhi Yang, Jingjing Wang, Daqing Ma, Cheng Qian, Meiping Lu, Jianhua Mao

{"title":"使用 CD19 靶向 CAR T 细胞治疗两名难治性系统性红斑狼疮儿科患者。","authors":"Xue He, Bin Hu, Yingzi Zhang, Fei Liu, Qiuyu Li, Chen Zheng, Junjie Shen, Zhi Yang, Jingjing Wang, Daqing Ma, Cheng Qian, Meiping Lu, Jianhua Mao","doi":"10.1016/j.autrev.2024.103692","DOIUrl":null,"url":null,"abstract":"Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising strategy for treating autoimmune diseases, particularly in systemic lupus erythematosus (SLE). However, CAR T-cell therapy for pediatric patients with SLE remains unexplored. Herein, we present a compelling investigation of two pediatric patients with refractory SLE who underwent infusion of CD19-targeted CAR T-cells. Patients 1 and 2 tolerated the CAR T-cell therapy well, which demonstrated remarkable efficacy after five and four months, respectively.","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"103692"},"PeriodicalIF":9.2000,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells.\",\"authors\":\"Xue He, Bin Hu, Yingzi Zhang, Fei Liu, Qiuyu Li, Chen Zheng, Junjie Shen, Zhi Yang, Jingjing Wang, Daqing Ma, Cheng Qian, Meiping Lu, Jianhua Mao\",\"doi\":\"10.1016/j.autrev.2024.103692\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising strategy for treating autoimmune diseases, particularly in systemic lupus erythematosus (SLE). However, CAR T-cell therapy for pediatric patients with SLE remains unexplored. Herein, we present a compelling investigation of two pediatric patients with refractory SLE who underwent infusion of CD19-targeted CAR T-cells. Patients 1 and 2 tolerated the CAR T-cell therapy well, which demonstrated remarkable efficacy after five and four months, respectively.\",\"PeriodicalId\":8664,\"journal\":{\"name\":\"Autoimmunity reviews\",\"volume\":\" \",\"pages\":\"103692\"},\"PeriodicalIF\":9.2000,\"publicationDate\":\"2024-11-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Autoimmunity reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.autrev.2024.103692\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Autoimmunity reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.autrev.2024.103692","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

嵌合抗原受体（CAR）T细胞疗法已成为治疗自身免疫性疾病，尤其是系统性红斑狼疮（SLE）的一种前景广阔的策略。然而，针对系统性红斑狼疮儿科患者的CAR T细胞疗法仍有待探索。在此，我们对两名接受CD19靶向CAR T细胞输注治疗的难治性系统性红斑狼疮儿科患者进行了令人信服的调查。患者1和2对CAR T细胞疗法耐受良好，分别在5个月和4个月后显示出显著疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells.

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising strategy for treating autoimmune diseases, particularly in systemic lupus erythematosus (SLE). However, CAR T-cell therapy for pediatric patients with SLE remains unexplored. Herein, we present a compelling investigation of two pediatric patients with refractory SLE who underwent infusion of CD19-targeted CAR T-cells. Patients 1 and 2 tolerated the CAR T-cell therapy well, which demonstrated remarkable efficacy after five and four months, respectively.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Autoimmunity reviews 医学-免疫学

CiteScore

24.70

自引率

4.40%

发文量

164

审稿时长

21 days

期刊介绍： Autoimmunity Reviews is a publication that features up-to-date, structured reviews on various topics in the field of autoimmunity. These reviews are written by renowned experts and include demonstrative illustrations and tables. Each article will have a clear "take-home" message for readers. The selection of articles is primarily done by the Editors-in-Chief, based on recommendations from the international Editorial Board. The topics covered in the articles span all areas of autoimmunology, aiming to bridge the gap between basic and clinical sciences. In terms of content, the contributions in basic sciences delve into the pathophysiology and mechanisms of autoimmune disorders, as well as genomics and proteomics. On the other hand, clinical contributions focus on diseases related to autoimmunity, novel therapies, and clinical associations. Autoimmunity Reviews is internationally recognized, and its articles are indexed and abstracted in prestigious databases such as PubMed/Medline, Science Citation Index Expanded, Biosciences Information Services, and Chemical Abstracts.